Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice
- PMID: 10692238
- DOI: 10.1006/clim.2000.4835
Fatal Mycobacterium bovis BCG infection in TNF-LT-alpha-deficient mice
Abstract
Neutralization of TNF or disruption of TNF-R1 leads to fatal Mycobacterium bovis BCG infection. Here we used TNF-LT-alpha-deficient mice to test whether a complete disruption of TNF and LT-alpha reduces further host resistance to BCG infection. The bacterial burden especially in the lungs of TNF-LT-alpha-deficient mice was significantly increased and the mice succumbed to infection between 8 and 10 weeks. In the absence of TNF-LT-alpha the granulomatous response was severely impaired and delayed. The cells in the granulomas of TNF-LT-alpha-deficient mice expressed low levels of MHC class II and ICAM-1. They contained a few T cells and F4/80-positive macrophages expressing little iNOS and acid phosphatase activity. By contrast, the lethal action of endotoxin was dramatically reduced in BCG-infected TNF-LT-alpha-deficient mice. In summary, in the absence of TNF-LT-alpha the recruitment and activation of mononuclear cells in response to BCG infection were significantly delayed and reduced resulting in immature granulomas allowing uncontrolled fatal infection.
Copyright 2000 Academic Press.
Similar articles
-
Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin.J Immunol. 1999 Mar 15;162(6):3504-11. J Immunol. 1999. PMID: 10092807
-
Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guérin infection in the absence of secreted TNF and lymphotoxin-alpha.J Immunol. 2002 Apr 1;168(7):3394-401. doi: 10.4049/jimmunol.168.7.3394. J Immunol. 2002. PMID: 11907097
-
Experimental Mycobacterium leprae infection in BALB/c mice: effect of BCG administration on TNF-alpha production and granuloma development.Int J Lepr Other Mycobact Dis. 2000 Jun;68(2):156-66. Int J Lepr Other Mycobact Dis. 2000. PMID: 11036496
-
Reactivation of tuberculosis by tumor necrosis factor neutralization.Eur Cytokine Netw. 2007 Mar;18(1):5-13. doi: 10.1684/ecn.2007.0083. Epub 2007 Mar 30. Eur Cytokine Netw. 2007. PMID: 17400533 Review.
-
The beneficial effects of localized tumor necrosis factor production in BCG infection.Behring Inst Mitt. 1991 Feb;(88):120-4. Behring Inst Mitt. 1991. PMID: 2049028 Review.
Cited by
-
Immunity against Mycobacterium tuberculosis and the risk of biologic anti-TNF-α reagents.Pediatr Rheumatol Online J. 2014 Oct 2;12:45. doi: 10.1186/1546-0096-12-45. eCollection 2014. Pediatr Rheumatol Online J. 2014. PMID: 25317081 Free PMC article. Review.
-
Innate myeloid cell TNFR1 mediates first line defence against primary Mycobacterium tuberculosis infection.Sci Rep. 2016 Mar 2;6:22454. doi: 10.1038/srep22454. Sci Rep. 2016. PMID: 26931771 Free PMC article.
-
Role of lymphotoxin in experimental models of infectious diseases: potential benefits and risks of a therapeutic inhibition of the lymphotoxin-beta receptor pathway.Infect Immun. 2005 Nov;73(11):7077-88. doi: 10.1128/IAI.73.11.7077-7088.2005. Infect Immun. 2005. PMID: 16239501 Free PMC article. Review. No abstract available.
-
Insights into ligand binding by a viral tumor necrosis factor (TNF) decoy receptor yield a selective soluble human type 2 TNF receptor.J Biol Chem. 2019 Mar 29;294(13):5214-5227. doi: 10.1074/jbc.RA118.005828. Epub 2019 Feb 5. J Biol Chem. 2019. PMID: 30723161 Free PMC article.
-
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clin Microbiol Rev. 2020 Jun 10;33(3):e00035-19. doi: 10.1128/CMR.00035-19. Print 2020 Jun 17. Clin Microbiol Rev. 2020. PMID: 32522746 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous